In vitro and in vivo evaluation of native glucagon and glucagon analog (MAR-D28) during aging: Lack of cytotoxicity and preservation of hyperglycemic effect

Journal of Diabetes Science and Technology

Volumn 4, Issue 6, 2010, Pages 1311-1321

  Ward, W Kenneth ^a   Massoud, Ryan G ^a   Szybala, Cory J ^a   Engle, Julia M ^a   El Youssef, Joseph ^b   Carroll, Julie M ^c   Roberts Jr, Charles T ^c   DiMarchi, Richard D ^d  

^a LEGACY HEALTH SYSTEM   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d INDIANA UNIVERSITY   (United States)

Author keywords

Amyloid; Cell culture; Cytotoxicity; Diabetes; Glucagon

Indexed keywords

AMYLOID; BUFFER; DRUG DERIVATIVE; GLUCAGON; OCTREOTIDE;

ANIMAL; ARTICLE; CELL STRAIN 3T3; CELL SURVIVAL; CHEMISTRY; DOSE RESPONSE; DRUG EFFECT; DRUG STABILITY; DRUG STORAGE; FIBROBLAST; GEL CHROMATOGRAPHY; GLUCOSE BLOOD LEVEL; METABOLISM; MOUSE; OSMOLARITY; PH; SUBCUTANEOUS DRUG ADMINISTRATION; SWINE; TIME;

AMYLOID; ANIMALS; BLOOD GLUCOSE; BUFFERS; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, GEL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG STABILITY; DRUG STORAGE; FIBROBLASTS; GLUCAGON; HYDROGEN-ION CONCENTRATION; INJECTIONS, SUBCUTANEOUS; MICE; NIH 3T3 CELLS; OCTREOTIDE; OSMOLAR CONCENTRATION; SWINE; TIME FACTORS;

EID: 79952994972     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229681000400604     Document Type: Conference Paper

References (13)

1. Pedersen JS, Dikov D, Flink JL, Hjuler HA, Christiansen G, Otzen DE. The changing face of glucagon fibrillation: structural polymorphism and conformational imprinting. J Mol Biol. 2006;355(3):501-23.
2. Onoue S, Ohshima K, Debari K, Koh K, Shioda S, Iwasa S, Kashimoto K, Yajima T. Mishandling of the therapeutic peptide glucagon generates cytotoxic amyloidogenic fibrils. Pharm Res. 2004;21(7):1274-83.
3. Castle JR, Engle JM, El Youssef J, Massoud RG, Yuen KC, Kagan R, Ward WK. Novel use of glucagon in a closed-loop system for prevention of hypoglycemia in type 1 diabetes. Diabetes Care. 2010;33(6)1282-7.
4. El-Khatib FH, Russell SJ, Nathan DM, Sutherlin RG, Damiano ER. A bihormonal closed-loop artificial pancreas for type 1 diabetes. Sci Transl Med. 2(27): 27ra27.
5. Ward WK, Engle J, Duman HM, Bergstrom CP, Kim S, I F. The benefit of subcutaneous glucagon during closed-loop glycemic control in rats with type 1 diabetes. IEEE Sensors. 2008;8(1):89-96.
6. El-Khatib FH, Jiang J, Gerrity RG, Damiano ER. Pharmacodynamics and stability of subcutaneously infused glucagon in a type 1 diabetic swine model in vivo. Diabetes Technol Ther. 2007;9(2):135-44.
7. Chabenne JR, DiMarchi MA, Gelfanov VM, DiMarchi RD. Optimization of the native glucagon sequence for medicinal purposes J Diabetes Sci Technol. 2010;4(6);1322-31.
8. Korzeniewski C, Callewaert DM. An enzyme-release assay for natural cytotoxicity. J Immunol Methods. 1983;64(3):313-20.
9. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65(1-2):55-63.
10. Klunk WE, Pettegrew JW, Abraham DJ. Quantitative evaluation of congo red binding to amyloid-like proteins with a beta-pleated sheet conformation. J Histochem Cytochem. 1989;37(8):1273-81.
11. Pedersen JS, Otzen DE. Amyloid-a state in many guises: survival of the fittest fibril fold. Protein Sci. 2008;17(1):2-10.
12. Maji SK, Perrin MH, Sawaya MR, Jessberger S, Vadodaria K, Rissman RA, Singru PS, Nilsson KP, Simon R, Schubert D, Eisenberg D, Rivier J, Sawchenko P, Vale W, Riek R. Functional amyloids as natural storage of peptide hormones in pituitary secretory granules. Science. 2009;325(5938):328-32.
13. Verma AK, da Silva JH, Kuhl DR. Diuretic effects of subcutaneous furosemide in human volunteers: a randomized pilot study. Ann Pharmacother. 2004;38(4):544-9.